Results 61 to 70 of about 4,707 (174)

From Innovation to Validation: Strengthening Interventional Radiology Through Data

Journal of Medical Imaging and Radiation Oncology, Volume 70, Issue 5, Page 457-461, August 2026.
Kaiwen Cabbabe, Gerard S. Goh, Charles Li, Matthew Lukies   +3 more
wiley   +1 more source

Successful use of intra venous tenecteplase for acute ischemic stroke in pregnancy

eNeurologicalSci
Intravenous thrombolysis (IVT) with tenecteplase or alteplase is the standard of care in, patients with Acute Ischemic Stroke (AIS) presenting within 3–4.5 h. However here, are no established guidelines for such treatment during pregnancy.
Balamurugan Namasivayam, Chitra Sengodan, Lavanya Mohanasundaram, Sathya Chinna Gounder, Madunisha Sivakumar   +4 more
doaj   +1 more source

Implementation of a Tenecteplase Protocol for Treatment of Acute Ischemic Stroke in a Health System

INNOVATIONS in Pharmacy
Purpose. Alteplase is the standard of care for intravenous thrombolytic treatment of acute ischemic stroke, but recent evidence suggests that tenecteplase may be as safe and efficacious. The purpose of this study was to evaluate the direct cost savings,
Alexis Pace, Maya Wai, Ethan Frye
doaj  

Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial

Stroke and Vascular Neurology
Background In ischaemic stroke, minor deficits (National Institutes of Health Stroke Scale (NIHSS) ≤5) at presentation are common but often progress, leaving patients with significant disability.
Dar Dowlatshahi, Mohammed A Almekhlafi, Tolulope Sajobi, Aleksandra Pikula, Ashfaq Shuaib, Alexandre Y Poppe, Richard H Swartz, Fouzi Bala, Ibrahim Alhabli, Aleksander Tkach, Heather Williams, Shelagh B Coutts, Nishita Singh, Anurag Trivedi, Andrew Demchuk, Gary Hunter, Brian H Buck, Faysal Benali, Bijoy Menon, MacKenzie Horn, Radhika Nair, Thalia Field, Mahesh Kate, Negar Asdaghi, Robert Sarmiento, Ayoola Ademola, Houman Khosravani, Herbert Alejandro Manosalva Alzate, Luciana Catanese   +28 more
doaj   +1 more source

Alteplase- and Tenecteplase-Related Errors and Risk Mitigation Strategies in the Treatment of Acute Ischemic Stroke: A Study of Event Reports From 52 Hospitals

Patient Safety
# Background Alteplase and tenecteplase are thrombolytic agents used to treat patients with acute ischemic stroke (AIS). Despite the convenient bolus dosing of tenecteplase, its off-label use for AIS creates new patient safety challenges that are ...
Myungsun Ro, Matthew A. Taylor, Rebecca Jones   +2 more
doaj   +1 more source

A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch

Stroke: Vascular and Interventional Neurology
Alteplase, a biosynthetic form of human tissue‐type plasminogen activator, is Food and Drug Administration‐approved for the treatment of acute ischemic stroke and currently the standard of care for thrombolytic therapy.
Miguel Rodriguez, Christian Sidebottom, Drew A. Wells, Thirumalaivasan Dhasakeerthi, Lisa Hayes, Cheran Elangovan, Balaji Krishnaiah   +6 more
doaj   +1 more source

Clinical benefit of tenecteplase despite failed recanalization in late-window ischemic stroke: a post hoc analysis of the TRACE-3 trial

BMC Medicine
Background The TRACE-3 trial established the efficacy of intravenous tenecteplase for patients with acute ischemic stroke and large vessel occlusion in the late time window.
Zhengzhao Lu, Ziran Wang, Aoming Jin, Fengyuan Che, Lihua Wang, Li Zhou, Hongguo Dai, Xintong Liu, Zhixin Cao, Liyuan Wang, Manjun Hao, Wanxing Ye, Yunyun Xiong, Yongjun Wang   +13 more
doaj   +1 more source

Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial

Stroke and Vascular Neurology
Background The benefit of intravenous alteplase in acute ischaemic stroke (AIS) is time-dependent. Tenecteplase is non-inferior to alteplase among patients with AIS.
Bruce C V Campbell, Yongjun Wang, Yilong Wang, Zixiao Li, Xingquan Zhao, David Wang, Yunyun Xiong, Hao Li, Xia Meng, Yuesong Pan, Lee H Schwamm, Aoming Jin, Mark W Parsons, Huaguang Zheng, Shuya Li, Runhui Li, Marc Fisher, Runqi Wangqin, Ziran Wang, Deyang Li, Hongguo Dai, Junhai Wang   +21 more
doaj   +1 more source

Comment on: Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke—The 24‐h Time‐Point May be a Pro‐Thrombotic Blind Spot: Check 6‐h Fibrinogen Rebound to Catch Early Re‐Occluders

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1299-1300, June 2026.
Qichao Fang, Luting Ying, Yongjin Gong
wiley   +1 more source

Should we switch to tenecteplase for all ischaemic strokes? Evidence and logistics [PDF]

Recent clinical trials provide robust evidence of non-inferiority of tenecteplase 0.25mg/kg over alteplase 0.9mg/kg in acute ischaemic stroke treated within 4.5h of time last known well.
Muir, Keith W.
core   +1 more source